Agency picks risk advisory panelist

Share this article:
The FDA's newly staffed Risk Communication Advisory Committee will begin reviewing risk communication issues in the first quarter of 2008. After sifting through 240 nominated individuals, the agency in November narrowed its selection down to 15 voting members with diverse backgrounds.

To chair the advisory committee, FDA selected Carnegie Mellon Howard Heinz university professor Baruch Fischhoff, whose expertise is in risk perception and communication. He will serve a four-year term on the committee. Panel members include television journalist and medical contributor on Good Morning America and ABCNews.com Prerna Mona Khanna; PR expert AnnaMaria DeSalva (Hill and Knowlton); and consumer advocate William K. Vaughn (Consumers Union).

The committee will advise the FDA about how best to communicate to the public about the risks and benefits of FDA-regulated products so as to facilitate their optimal use.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.